Investigating the mechanisms of drug sensitivity and resistance to targeted therapies for lung cancer.
How do tumor cells evolve during treatment? Can we slow or halt the evolution of acquired drug resistance?
Are all cells within a tumor created equal? Why are some cells killed by therapy while other are able to survive?
Why do targeted therapies stop working? Can we develop new therapies to overcome drug resistance?
Can we combine orthogonal targeted therapy and immunotherapy approaches to better fight lung cancer?
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Our mission is to advance the development of new therapies for patients with lung cancer through scientific discovery of the molecular mechanisms of drug sensitivity and resistance, understanding tumor evolution during treatment, and identification of targetable vulnerabilities to guide investigation of novel therapeutic strategies.
We are a diverse group of physicians & scientists with expertise in cell biology, pharmacology, genetics, immunology and computational biology.Meet the Team
Congratulations to Wafa for passing her Preliminary Qualifying Exam for the Harvard BBS Program today!Go to News
Aaron speaks at the University of Colorado Cancer Center. Thank you to Dr. Sabrina Spencer for hosting. A great opportunity to make new friends and reconnect with former colleagues and…Go to News
We are looking for people to partner with us in our mission to improve treatments for patients with lung cancer.Join Us Support Us
We are privileged to partner with a number of individuals and organizations who support our research. We are grateful for their dedication to helping us in the fight against lung cancer.